• LAST PRICE
    0.8220
  • TODAY'S CHANGE (%)
    Trending Down-0.0280 (-3.2941%)
  • Bid / Lots
    0.8217/ 1
  • Ask / Lots
    0.8500/ 2
  • Open / Previous Close
    0.8450 / 0.8500
  • Day Range
    Low 0.8216
    High 0.8499
  • 52 Week Range
    Low 0.2500
    High 1.5000
  • Volume
    11,222
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 0.85
TimeVolumeORGS
09:34 ET10000.84
09:38 ET43520.84
10:03 ET2000.8499
01:17 ET3000.84
01:48 ET5000.844949
01:50 ET5640.8498
02:08 ET3000.83
02:18 ET9470.8216
02:36 ET1000.8216
03:07 ET1000.849899
03:12 ET9960.822
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesORGS
Orgenesis Inc
27.4M
-0.9x
---
United StatesSNWV
SANUWAVE Health Inc
24.6M
-0.5x
---
United StatesDFCO
Dalrada Financial Corp
13.6M
-0.6x
---
United StatesPOCI
Precision Optics Corporation Inc
33.7M
-19.2x
---
United StatesDRIO
DarioHealth Corp
41.6M
-0.7x
---
United StatesDMTK
DermTech Inc
24.3M
-0.2x
---
As of 2024-03-29

Company Information

Orgenesis Inc. is a biotech company focused on cell and gene therapies (CGTs). The Company focuses on the development of autologous therapies that can be manufactured under processes and systems that are developed for each therapy using a closed and automated approach that is validated for compliant production near the patient for treatment of the patient at the point of care. It operates in two segments: Octomera LLC (Octomera segment) and therapies related activities (Therapies segment). Octomera segment includes mainly point of care (POCare) services. The Therapies segment includes the Company’s therapeutic development operations. The POCare Services platform is utilized by parties, such as biotech companies and hospitals for the supply of their products. Octomera’s services include adapting the process to the platform and supplying the products; adaptation of automation and closed systems to serviced therapies, and contract research organization services for clinical trials.

Contact Information

Headquarters
20271 Goldenrod LaneGERMANTOWN, MD, United States 20876
Phone
480-659-6404
Fax
---

Executives

Chairperson of the Board of Directors, Chief Executive Officer
Vered Caplan
Chief Financial Officer
Victor Miller
Independent Director
Yaron Adler
Independent Director
Ashish Nanda
Independent Director
Mario Philips

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$27.4M
Revenue (TTM)
$27.8M
Shares Outstanding
33.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.07
EPS
$-0.90
Book Value
$1.08
P/E Ratio
-0.9x
Price/Sales (TTM)
1.0
Price/Cash Flow (TTM)
---
Operating Margin
-67.88%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.